Report Detail
Global Acinetobacter Infections Treatment Market Insights, Forecast to 2025
- RnM2923660 |
- 09 March, 2019 |
- Global |
- 112 Pages |
- QYResearch |
- Pharma & Healthcare
Acinetobacter is a group of bacteria commonly found in soil and water. While there are many types or “species” of Acinetobacter and all can cause human disease, Acinetobacter baumannii accounts for about 80% of reported infections.
Outbreaks of Acinetobacter infections typically occur in intensive care units and healthcare settings housing very ill patients. Acinetobacter infections rarely occur outside of healthcare settings.
Acinetobacter is often resistant to many commonly prescribed antibiotics. Decisions on treatment of infections with Acinetobacter should be made on a case-by-case basis by a healthcare provider. Acinetobacter infection typically occurs in ill patients and can either cause or contribute to death in these patients.
In the last several years, global market of Acinetobacter Infections Treatment developed rapidly, with an average growth rate of 2.96%. In 2016, United States Market Size of Acinetobacter Infections Treatment is nearly 22 M USD. For developing product, there are 1 in Phase III, 1 in Phase Ⅱ, 4 in Phase 1 and 8 in Preclinical. The total investment for Acinetobacter Infections Treatmen Drugs developing is around 90 M USD.
The global average Cost of Acinetobacter Infections Treatment is in the decreasing trend, from 2901 USD/Case in 2012 to2870 USD/Case in 2016. With the situation of global economy, prices will be in decreasing trend in the following five years.
The classification of Acinetobacter Infections Treatment includes Sulbactam, Carbapenems , Aminoglycosides, Polymyxins, Tigecycline and Others Treatment, and the proportion of Aminoglycosides in 2016 is about 18%, and the proportion is in decreasing trend from 2012 to 2016.
The global Acinetobacter Infections Treatment market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Acinetobacter Infections Treatment market based on company, product type, end user and key regions.
This report studies the global market size of Acinetobacter Infections Treatment in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Acinetobacter Infections Treatment in these regions.
This research report categorizes the global Acinetobacter Infections Treatment market by top players/brands, region, type and end user. This report also studies the global Acinetobacter Infections Treatment market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Entasis Therapeutics
Roche
Adenium Biotech
Vaxdyn
Hsiri Therapeutics
Aridis Pharmaceuticals
LegoChem Biosciences
Atterx Biotherapeutics
Achaogen
Peptilogics
Sealife PHARMA
Shionogi
Techulon
Tetraphase Pharmaceuticals
Market size by Product
Sulbactam
Carbapenems
Aminoglycosides
Polymyxins
Tetracyclines
Others
Market size by End User
Application I
Application II
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Acinetobacter Infections Treatment market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Acinetobacter Infections Treatment market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Acinetobacter Infections Treatment companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Acinetobacter Infections Treatment submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Acinetobacter Infections Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (Cases). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Acinetobacter Infections Treatment market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Acinetobacter Infections Treatment Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Acinetobacter Infections Treatment Market Size Growth Rate by Product
- 1.4.2 Sulbactam
- 1.4.3 Carbapenems
- 1.4.4 Aminoglycosides
- 1.4.5 Polymyxins
- 1.4.6 Tetracyclines
- 1.4.7 Others
- 1.5 Market by End User
- 1.5.1 Global Acinetobacter Infections Treatment Market Size Growth Rate by End User
- 1.5.2 Application I
- 1.5.3 Application II
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Acinetobacter Infections Treatment Market Size
- 2.1.1 Global Acinetobacter Infections Treatment Revenue 2014-2025
- 2.1.2 Global Acinetobacter Infections Treatment Sales 2014-2025
- 2.2 Acinetobacter Infections Treatment Growth Rate by Regions
- 2.2.1 Global Acinetobacter Infections Treatment Sales by Regions
- 2.2.2 Global Acinetobacter Infections Treatment Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Acinetobacter Infections Treatment Sales by Manufacturers
- 3.1.1 Acinetobacter Infections Treatment Sales by Manufacturers
- 3.1.2 Acinetobacter Infections Treatment Sales Market Share by Manufacturers
- 3.1.3 Global Acinetobacter Infections Treatment Market Concentration Ratio (CR5 and HHI)
- 3.2 Acinetobacter Infections Treatment Revenue by Manufacturers
- 3.2.1 Acinetobacter Infections Treatment Revenue by Manufacturers (2014-2019)
- 3.2.2 Acinetobacter Infections Treatment Revenue Share by Manufacturers (2014-2019)
- 3.3 Acinetobacter Infections Treatment Price by Manufacturers
- 3.4 Acinetobacter Infections Treatment Manufacturing Base Distribution, Product Types
- 3.4.1 Acinetobacter Infections Treatment Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Acinetobacter Infections Treatment Product Type
- 3.4.3 Date of International Manufacturers Enter into Acinetobacter Infections Treatment Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Acinetobacter Infections Treatment Sales by Product
- 4.2 Global Acinetobacter Infections Treatment Revenue by Product
- 4.3 Acinetobacter Infections Treatment Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Acinetobacter Infections Treatment Breakdown Data by End User
6 North America
- 6.1 North America Acinetobacter Infections Treatment by Countries
- 6.1.1 North America Acinetobacter Infections Treatment Sales by Countries
- 6.1.2 North America Acinetobacter Infections Treatment Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Acinetobacter Infections Treatment by Product
- 6.3 North America Acinetobacter Infections Treatment by End User
7 Europe
- 7.1 Europe Acinetobacter Infections Treatment by Countries
- 7.1.1 Europe Acinetobacter Infections Treatment Sales by Countries
- 7.1.2 Europe Acinetobacter Infections Treatment Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Acinetobacter Infections Treatment by Product
- 7.3 Europe Acinetobacter Infections Treatment by End User
8 Asia Pacific
- 8.1 Asia Pacific Acinetobacter Infections Treatment by Countries
- 8.1.1 Asia Pacific Acinetobacter Infections Treatment Sales by Countries
- 8.1.2 Asia Pacific Acinetobacter Infections Treatment Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Acinetobacter Infections Treatment by Product
- 8.3 Asia Pacific Acinetobacter Infections Treatment by End User
9 Central & South America
- 9.1 Central & South America Acinetobacter Infections Treatment by Countries
- 9.1.1 Central & South America Acinetobacter Infections Treatment Sales by Countries
- 9.1.2 Central & South America Acinetobacter Infections Treatment Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Acinetobacter Infections Treatment by Product
- 9.3 Central & South America Acinetobacter Infections Treatment by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Acinetobacter Infections Treatment by Countries
- 10.1.1 Middle East and Africa Acinetobacter Infections Treatment Sales by Countries
- 10.1.2 Middle East and Africa Acinetobacter Infections Treatment Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Acinetobacter Infections Treatment by Product
- 10.3 Middle East and Africa Acinetobacter Infections Treatment by End User
11 Company Profiles
- 11.1 Entasis Therapeutics
- 11.1.1 Entasis Therapeutics Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Entasis Therapeutics Acinetobacter Infections Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Entasis Therapeutics Acinetobacter Infections Treatment Products Offered
- 11.1.5 Entasis Therapeutics Recent Development
- 11.2 Roche
- 11.2.1 Roche Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Roche Acinetobacter Infections Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Roche Acinetobacter Infections Treatment Products Offered
- 11.2.5 Roche Recent Development
- 11.3 Adenium Biotech
- 11.3.1 Adenium Biotech Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Adenium Biotech Acinetobacter Infections Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Adenium Biotech Acinetobacter Infections Treatment Products Offered
- 11.3.5 Adenium Biotech Recent Development
- 11.4 Vaxdyn
- 11.4.1 Vaxdyn Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Vaxdyn Acinetobacter Infections Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Vaxdyn Acinetobacter Infections Treatment Products Offered
- 11.4.5 Vaxdyn Recent Development
- 11.5 Hsiri Therapeutics
- 11.5.1 Hsiri Therapeutics Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Hsiri Therapeutics Acinetobacter Infections Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Hsiri Therapeutics Acinetobacter Infections Treatment Products Offered
- 11.5.5 Hsiri Therapeutics Recent Development
- 11.6 Aridis Pharmaceuticals
- 11.6.1 Aridis Pharmaceuticals Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Aridis Pharmaceuticals Acinetobacter Infections Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Aridis Pharmaceuticals Acinetobacter Infections Treatment Products Offered
- 11.6.5 Aridis Pharmaceuticals Recent Development
- 11.7 LegoChem Biosciences
- 11.7.1 LegoChem Biosciences Company Details
- 11.7.2 Company Business Overview
- 11.7.3 LegoChem Biosciences Acinetobacter Infections Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 LegoChem Biosciences Acinetobacter Infections Treatment Products Offered
- 11.7.5 LegoChem Biosciences Recent Development
- 11.8 Atterx Biotherapeutics
- 11.8.1 Atterx Biotherapeutics Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Atterx Biotherapeutics Acinetobacter Infections Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Atterx Biotherapeutics Acinetobacter Infections Treatment Products Offered
- 11.8.5 Atterx Biotherapeutics Recent Development
- 11.9 Achaogen
- 11.9.1 Achaogen Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Achaogen Acinetobacter Infections Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Achaogen Acinetobacter Infections Treatment Products Offered
- 11.9.5 Achaogen Recent Development
- 11.10 Peptilogics
- 11.10.1 Peptilogics Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Peptilogics Acinetobacter Infections Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Peptilogics Acinetobacter Infections Treatment Products Offered
- 11.10.5 Peptilogics Recent Development
- 11.11 Sealife PHARMA
- 11.12 Shionogi
- 11.13 Techulon
- 11.14 Tetraphase Pharmaceuticals
12 Future Forecast
- 12.1 Acinetobacter Infections Treatment Market Forecast by Regions
- 12.1.1 Global Acinetobacter Infections Treatment Sales Forecast by Regions 2019-2025
- 12.1.2 Global Acinetobacter Infections Treatment Revenue Forecast by Regions 2019-2025
- 12.2 Acinetobacter Infections Treatment Market Forecast by Product
- 12.2.1 Global Acinetobacter Infections Treatment Sales Forecast by Product 2019-2025
- 12.2.2 Global Acinetobacter Infections Treatment Revenue Forecast by Product 2019-2025
- 12.3 Acinetobacter Infections Treatment Market Forecast by End User
- 12.4 North America Acinetobacter Infections Treatment Forecast
- 12.5 Europe Acinetobacter Infections Treatment Forecast
- 12.6 Asia Pacific Acinetobacter Infections Treatment Forecast
- 12.7 Central & South America Acinetobacter Infections Treatment Forecast
- 12.8 Middle East and Africa Acinetobacter Infections Treatment Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Acinetobacter Infections Treatment Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Acinetobacter Infections Treatment . Industry analysis & Market Report on Acinetobacter Infections Treatment is a syndicated market report, published as Global Acinetobacter Infections Treatment Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Acinetobacter Infections Treatment market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
